세계의 장기이식 거부반응 억제제 시장 규모 조사 및 예측 : 약물 종류별, 이식 유형별, 유통 채널별, 지역별 분석(2023-2030년)

Global Organ Transplant Rejection Medication Market is valued at approximately USD 4.9 billion in 2022 and is anticipated to grow with a growth rate of more than 3.9% over the forecast period 2023-2030. Organ transplantation is a surgical procedure in which tissue, or an organ is transferred from one person's body to another person's body. Organ transplant rejection medication is used to prevent organ rejection in transplant recipients. The rising incidence of chronic disease and the increased incidence of organ failure are the key factors responsible for the market growth of the Organ Transplant Rejection Medication Market over the forecast period.

According to the Health Resources and Services Administration. In 2022, in the U.S., more than 42,887 organ transplants were performed and it's an increase of 3.7% over 2021. Also, according to the Department of Health & Human Services, in Mar 2023, approximately 104,234 patients across the globe were waiting to receive organs for transplant. Thus, the rising incidence of chronic disease and the increased incidence of organ failure are fueling the market demand across the globe. Also, advancements in technology, such as new surgical techniques and immunosuppressive drugs and a rise in the number of organ donors accelerate market growth. Moreover, increased awareness about the benefits of organ transplantation in an aging population and an increase in funding for research and development are anticipated to create lucrative growth opportunities for the market. However, the high cost and complex procedures stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Organ Transplant Rejection Medication Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in terms of revenue owing to factors such as the rising incidence of chronic disease, favorable reimbursement policies, technological advancement and the presence of advanced healthcare infrastructure create market growth in this region. Asia-Pacific is the fastest-growing region due to increasing incidence of chronic diseases, rising healthcare expenditure, rise in affordability and increased awareness about organ rejection medications in the region.

Major market player included in this report are:

• Pfizer, Inc.
• Astellas Pharma Global Development, Inc.
• F, Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• AbbVie Inc.
• Viatris, Inc.
• Hikma Pharmaceuticals plc.
• Teva Pharmaceutical Industries Ltd
• Cadila Healthcare Limited

Recent Developments in the Market:

• In August 2022, Strides gained USFDA certification for their Cyclosporine Softgel Capsule. Strides strengthened its market position by adding Cyclosporine Softgel capsules, Tacrolimus capsules and an immunosuppressive medicine line for the US market.

Global Organ Transplant Rejection Medication Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Drug Class, Transplant Type, Distribution channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Antibodies
• Antimetabolites
• Calcineurin Inhibitors
• mTOR Inhibitors
• Steroids

By Transplant Type:

• Kidney
• Liver
• Heart
• Lung
• Pancreas
• Others

By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada

• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

• Latin America
• Brazil
• Mexico

• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Organ Transplant Rejection Medication Market, by region, 2020-2030 (USD Billion)
  • 1.2.2. Organ Transplant Rejection Medication Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.2.3. Organ Transplant Rejection Medication Market, by Transplant Type, 2020-2030 (USD Billion)
  • 1.2.4. Organ Transplant Rejection Medication Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Organ Transplant Rejection Medication Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Organ Transplant Rejection Medication Market Dynamics

• 3.1. Organ Transplant Rejection Medication Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising incidence of chronic disease
    • 3.1.1.2. Increased incidence of organ failure
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of medication
    • 3.1.2.2. Complex procedures of organ transplant
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increased awareness about the benefits of organ transplantation
    • 3.1.3.2. Increase in funding for research and development

Chapter 4. Global Organ Transplant Rejection Medication Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economic
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Organ Transplant Rejection Medication Market, by Drug Class

• 5.1. Market Snapshot
• 5.2. Global Organ Transplant Rejection Medication Market by Drug Class, Performance - Potential Analysis
• 5.3. Global Organ Transplant Rejection Medication Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
• 5.4. Organ Transplant Rejection Medication Market, Sub Segment Analysis
  • 5.4.1. Antibodies
  • 5.4.2. Antimetabolites
  • 5.4.3. Calcineurin Inhibitors
  • 5.4.4. mTOR Inhibitors
  • 5.4.5. Steroids

Chapter 6. Global Organ Transplant Rejection Medication Market, by Transplant Type

• 6.1. Market Snapshot
• 6.2. Global Organ Transplant Rejection Medication Market by Transplant Type, Performance - Potential Analysis
• 6.3. Global Organ Transplant Rejection Medication Market Estimates & Forecasts by Transplant Type 2020-2030 (USD Billion)
• 6.4. Organ Transplant Rejection Medication Market, Sub Segment Analysis
  • 6.4.1. Kidney
  • 6.4.2. Liver
  • 6.4.3. Heart
  • 6.4.4. Lung
  • 6.4.5. Pancreas
  • 6.4.6. Others

Chapter 7. Global Organ Transplant Rejection Medication Market, by Distribution Channel

• 7.1. Market Snapshot
• 7.2. Global Organ Transplant Rejection Medication Market by Distribution Channel, Performance - Potential Analysis
• 7.3. Global Organ Transplant Rejection Medication Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 7.4. Organ Transplant Rejection Medication Market, Sub Segment Analysis
  • 7.4.1. Hospitals Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies

Chapter 8. Global Organ Transplant Rejection Medication Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Organ Transplant Rejection Medication Market, Regional Market Snapshot
• 8.4. North America Organ Transplant Rejection Medication Market
  • 8.4.1. U.S. Organ Transplant Rejection Medication Market
    • 8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Transplant Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Organ Transplant Rejection Medication Market
• 8.5. Europe Organ Transplant Rejection Medication Market Snapshot
  • 8.5.1. U.K. Organ Transplant Rejection Medication Market
  • 8.5.2. Germany Organ Transplant Rejection Medication Market
  • 8.5.3. France Organ Transplant Rejection Medication Market
  • 8.5.4. Spain Organ Transplant Rejection Medication Market
  • 8.5.5. Italy Organ Transplant Rejection Medication Market
  • 8.5.6. Rest of Europe Organ Transplant Rejection Medication Market
• 8.6. Asia-Pacific Organ Transplant Rejection Medication Market Snapshot
  • 8.6.1. China Organ Transplant Rejection Medication Market
  • 8.6.2. India Organ Transplant Rejection Medication Market
  • 8.6.3. Japan Organ Transplant Rejection Medication Market
  • 8.6.4. Australia Organ Transplant Rejection Medication Market
  • 8.6.5. South Korea Organ Transplant Rejection Medication Market
  • 8.6.6. Rest of Asia Pacific Organ Transplant Rejection Medication Market
• 8.7. Latin America Organ Transplant Rejection Medication Market Snapshot
  • 8.7.1. Brazil Organ Transplant Rejection Medication Market
  • 8.7.2. Mexico Organ Transplant Rejection Medication Market
• 8.8. Middle East & Africa Organ Transplant Rejection Medication Market
  • 8.8.1. Saudi Arabia Organ Transplant Rejection Medication Market
  • 8.8.2. South Africa Organ Transplant Rejection Medication Market
  • 8.8.3. Rest of Middle East & Africa Organ Transplant Rejection Medication Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Pfizer, Inc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Astellas Pharma Global Development, Inc.
  • 9.3.3. F, Hoffmann-La Roche Ltd.
  • 9.3.4. Bristol-Myers Squibb Company
  • 9.3.5. GlaxoSmithKline plc.
  • 9.3.6. AbbVie Inc.
  • 9.3.7. Viatris, Inc.
  • 9.3.8. Hikma Pharmaceuticals plc.
  • 9.3.9. Teva Pharmaceutical Industries Ltd,
  • 9.3.10. Cadila Healthcare Limited

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption